<DOC>
	<DOCNO>NCT01832896</DOCNO>
	<brief_summary>The objective study evaluate safety tolerability single Subcutaneous ( SC ) dose Ecallantide child adolescent Hereditary Angioedema ( HAE ) .</brief_summary>
	<brief_title>Study Assess Tolerability Safety Ecallantide Children Adolescents With Hereditary Angioedema</brief_title>
	<detailed_description>This pilot study open-label , non-randomized , single-arm study evaluate tolerability safety single SC administration ecallantide approximately 10 pediatric subject HAE initial acute attack . The study plan enroll subject 2 15 year age present acute cutaneous , abdominal , laryngeal HAE attack . No 3 study site include goal 10 patient achieve . After treatment initial attack , one additional open label treatment ecallantide offer subject contingent upon treat previously present subsequent acute cutaneous , abdominal , laryngeal attack HAE least 7 day initial treatment . Open-label treatment second HAE attack continue 10 patient treated initial attack . Safety evaluation perform subsequent ecallantide-treated attack initial treat attack</detailed_description>
	<mesh_term>Angioedema</mesh_term>
	<mesh_term>Angioedemas , Hereditary</mesh_term>
	<mesh_term>Hereditary Angioedema Types I II</mesh_term>
	<criteria>1 . 2 15 year age , inclusive ( ie , second birthday day prior sixteenth birthday ) time subject 's first attack . 2 . Documented diagnosis HAE type I II . Diagnosis must confirm documented immunogenic ( low limit normal ) and/or functional ( &lt; 50 % normal level ) C1 Inhibitor deficiency . Diagnosis may basis historic data diagnostic test conducted time screen . 3 . Informed consent ( subject assent appropriate ) sign subject 's parent ( ) legal guardian ( ) . 1 . History adverse reaction ( AE ) Ecallantide past 2 . Diagnosis angioedema HAE 3 . Participation another clinical study 30 day prior treatment 4 . Any known factor/disease might interfere treatment compliance , study conduct , result interpretation 5 . Congenital acquire cardiac anomaly interfere significantly cardiac function . 6 . Treatment angiotensin convert enzyme ( ACE ) inhibitor within 7 day prior treatment . 7 . Use hormonal contraception within 90 day prior treatment female childbearing potential 8 . The subject pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Hereditary Angioedema</keyword>
	<keyword>Children</keyword>
	<keyword>Adolescents</keyword>
	<keyword>Ecallantide</keyword>
</DOC>